NCT01858831已完成1 期
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- plasma atovaquone concentration
研究概览
简要总结
This study will be a single-center, phase I, randomized, open, in fed condition, parallel, single dose study to evaluate the pharmacokinetics and the safety, tolerability of Atovaquone/proguanil combination tablets and atovaquone suspension in Japanese healthy male subjects.
Serial blood samples will be collected for the determination of the plasma concentration of atovaquone, proguanil and cycloguanil after dosing of atovaquone 1000mg/proguanil 400 mg and the plasma atovaquone concentration of atovaquone 750 and 1500 mg. Safety assessments will be performed for each treatment group.
CYP2C19 contribute to proguanil metabolism. CYP2C19 genotype will be determined in atovaquone/proguanil dosing group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy as defined as being free from clinically significant illness or disease as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital sign, laboratory tests and ECG.
- •Japanese healthy male between 20 and 55 years of age inclusive, at the time of signing the informed consent.
- •Body weight => 50 kg and BMI within the range 18.5- 25 kg/m2
- •Non-smoker or ex-smoker having ceased smoking for at least 6 months. (inclusive).
- •ALT, alkaline phosphatase and bilirubin below the upper limit of normal (ULN)
- •Single QTcB< 450 msec.
- •Vital sign within the following ranges; Systolic blood pressure: < 90 mmHg or > 140 mmHg, Diastolic blood pressure: < 45 mmHg or > 90 mmHg, Plus rate: < 45 bpm or > 100 bpm, Body temperature: 37.5 C
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •A positive results of syphilis, HBs antigen, HCV antibody, HIV antibody and HTLV-1 antibody at the time of screening.
- •History of any cardiac diseases irrespective of with or without symptom.
- •An episode of cardiac syncope within one year before screening period.
- •History/evidence of clinically significant pulmonary diseases and hyper/hypo-thyroidism.
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive pre-study drug screen.
- •History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.
- •The subject had participated in a clinical study or post-marketing study with an investigational or a non-investigational product during the previous 4 months preceding the administration of study medication of this study.
- •The subject had participated in a clinical study or post-marketing study with an investigational or a non-investigational product during the previous 4 months preceding the administration of study medication of this study.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Unable to refrain from the use of alcohol, prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy excluding pollen allergy without current symptoms.
- •Where participation in the study would result in donation of blood or blood products in excess of 400 mL within a 4 month or 200 mL within 2 month.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
研究组 & 干预措施
Atovaquone 1500 mg
Active Comparator
Atovaquone 1500 mg
干预措施: Atovaquone (Drug)
Atovaquone 750 mg
Active Comparator
Atovaquone 750 mg
干预措施: Atovaquone (Drug)
Atovaquone/proguanil HCL
Experimental
Atovaquone/proguanil HCL
干预措施: Atovaquone/proguanil HCL (Drug)
结局指标
主要结局
plasma atovaquone concentration
时间窗: pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
plasma proguanil concentration
时间窗: pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
plasma cycloguanil concentration
时间窗: pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose
次要结局
- Change in Diastolic Blood Pressure(at pre-dose, 4, 24, 72, 168 and 336 h post-dose)
- Change in Heart rate(at pre-dose, 4, 24, 72, 168 and 336 h post-dose)
- Number of participants with adverse events(up to 336h post dose)
- Change in Systolic Blood Pressure(at pre-dose, 4, 24, 72, 168 and 336 h post-dose)
- Change in ECG findings(at pre-dose, 4, 72, 168 and 336 h post-dose)
- Laboratory(at pre-dose, 72, 168 and 336 h post-dose)
- Change in Biochemistry values(at pre-dose, 72, 168 and 336 h post-dose)
- Change in Urinalysis values(at pre-dose, 72, 168 and 336 h post-dose)
- Change in Hematology values(at pre-dose, 72, 168 and 336 h post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential HypertensionEssential HypertensionNCT05880056Genuine Research Center, Egypt406
终止
1 期
MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionHepatic ImpairmentNCT02050815Array Biopharma, now a wholly owned subsidiary of Pfizer27
已完成
1 期
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic ImpairmentHepatic ImpairmentNCT03713242Idorsia Pharmaceuticals Ltd.32
已完成
1 期
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24
已完成
1 期
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780Hepatic ImpairmentNCT06576765AstraZeneca16